Peakdale Molecular has for the first time, extended its novel intermediates catalogue mid-year, providing its clients with over 575 non-exclusive compounds for their drug programmes
Using its innovative chemistry, the company has designed and synthesised a catalogue of unique building blocks, key to creating diversity and novelty in drug discovery programmes.
The mid-year additions to the catalogue include isomers of existing products where Peakdale's chemists have synthesised more unusual substituents, as well as some of the company's popular core molecules with different functionalities, such as the 6-(trifluoromethyl)pyridines.
Gareth Jenkins, business development manager at Peakdale, commented, "Peakdale's business was originally built upon our ability to design and synthesise useful intermediates for pharmaceutical research. "Our catalogue provides access to an array of practical building blocks and many of these novel compounds are currently in various stages of our clients' drug discovery and development pipelines".
Peakdale says it has built a reputation for delivering its compounds on time and in full and the new additions to the intermediates catalogue are available in research quantities from stock.
In addition the company's kilo lab facilities allow production of these intermediates in 100g-1kg quantities, with lead times from only four to six weeks.
